Olive Oil Recall: Ocaliva Withdrawn From US Market
- Intercept Pharmaceuticals has voluntarily removed its drug Ocaliva (obeticholic acid) from the United States market. This action follows a direct request from the Food and Drug Administration (FDA),...
- Ocaliva is a medication approved in 2016 for the treatment of primary biliary cholangitis (PBC), a chronic liver disease in which bile ducts in the liver are slowly...
- It was initially approved as a second-line treatment for PBC patients who hadn't adequately responded to ursodeoxycholic acid (UDCA), the standard first-line therapy.
“`html
Ocaliva Withdrawn from US Market After FDA request
Table of Contents
Intercept Pharmaceuticals has voluntarily removed its drug Ocaliva (obeticholic acid) from the United States market. This action follows a direct request from the Food and Drug Administration (FDA), which has also placed a clinical hold on all ongoing trials involving the medication. The move raises notable questions for patients currently using Ocaliva and those who may have been candidates for treatment.
What is ocaliva and What Was It Used For?
Ocaliva is a medication approved in 2016 for the treatment of primary biliary cholangitis (PBC), a chronic liver disease in which bile ducts in the liver are slowly destroyed. PBC affects approximately 1 in 1,000 women and 1 in 10,000 men, ofen leading to cirrhosis, liver failure, and the need for liver transplantation. Ocaliva works by activating the farnesoid X receptor (FXR), a nuclear receptor that plays a role in regulating bile acid metabolism.
It was initially approved as a second-line treatment for PBC patients who hadn’t adequately responded to ursodeoxycholic acid (UDCA), the standard first-line therapy. Later, its use was expanded to include patients with early-stage PBC, even before UDCA treatment failed.
Why Was Ocaliva Pulled From the Market?
The FDA’s request for withdrawal and the subsequent clinical hold stem from safety concerns identified in a post-marketing study. Specifically, the study revealed a higher-than-expected risk of serious liver injury and death in patients taking Ocaliva, particularly those with advanced PBC. the FDA determined that the risks associated with the drug outweighed its benefits, prompting the action.
The initial concerns arose from signals detected in real-world data,leading to the required post-marketing study. This highlights the importance of ongoing monitoring of drug safety even after approval.
What Does This Mean for Patients Currently Taking Ocaliva?
Patients currently prescribed Ocaliva should immediately consult with their healthcare provider. Discontinuing Ocaliva abruptly can have consequences, and a carefully managed transition to an alternative treatment plan is crucial. There are other treatment options available for PBC, including UDCA and fibrates, and a physician can determine the most appropriate course of action based on individual patient circumstances.
The FDA advises patients to report any adverse effects to the agency’s MedWatch program. Resources for PBC patients, including support groups and information about the disease, are available through organizations like the PBC Foundation.
Impact on ongoing Clinical Trials
The FDA’s clinical hold extends to all ongoing trials involving Ocaliva, effectively halting further research into its potential uses. Intercept Pharmaceuticals had been investigating Ocaliva for other liver diseases, including nonalcoholic steatohepatitis (NASH).The clinical hold casts significant doubt on the future of these investigations.
This pause in research represents a setback for patients with these conditions, as Ocaliva had shown some promise in early studies. However, patient safety remains the paramount concern.